---
title: "Sihuan’s Xuanzhu Biopharm Completes Full H Share Circulation in Hong Kong"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286072114.md"
description: "Sihuan Pharmaceutical's subsidiary, Xuanzhu Biopharm, has completed the full circulation of its H shares, converting over 357 million previously unlisted shares. This brings Xuanzhu's total issued share capital to nearly 518 million H shares on the Hong Kong Stock Exchange. The move enhances liquidity and market access, supporting Sihuan's strategy in the biopharmaceutical sector. Sihuan, founded in 2001 and listed since 2010, focuses on innovative drugs and aims to lead in medical aesthetics and biopharma in China."
datetime: "2026-05-12T09:40:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286072114.md)
  - [en](https://longbridge.com/en/news/286072114.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286072114.md)
---

# Sihuan’s Xuanzhu Biopharm Completes Full H Share Circulation in Hong Kong

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The latest update is out from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ).

Sihuan Pharmaceutical announced that its non-wholly-owned subsidiary Xuanzhu Biopharm has completed the full circulation of its H shares, converting 357,245,794 previously unlisted shares into H shares. Following the conversion, Xuanzhu’s entire issued share capital of 517,947,790 shares now trades as H shares on the Hong Kong Stock Exchange.

Xuanzhu Biopharm, listed in Hong Kong since October 2025, focuses on innovative drugs targeting major diseases in digestion, oncology and non-alcoholic steatohepatitis, supported by dual R&D platforms in small molecules and large-molecule biopharmaceuticals. The move to full H share circulation enhances liquidity and market accessibility for Xuanzhu, strengthening Sihuan’s positioning in China’s innovative biopharmaceutical sector and supporting its two-wheel drive strategy in medical aesthetics and biopharma.

**More about Sihuan Pharmaceutical Holdings Group**

Sihuan Pharmaceutical Holdings Group is an international medical aesthetics and pharmaceutical company founded in 2001 and listed in Hong Kong since 2010. The group operates an innovation-led model with a strong R&D platform, broad global product pipeline, efficient multi-dosage manufacturing and a mature sales network, aiming to become a leading medical aesthetics and biopharmaceutical player in China.

**Average Trading Volume:** 28,740,971

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$11.38B

### Related Stocks

- [00460.HK](https://longbridge.com/en/quote/00460.HK.md)
- [02575.HK](https://longbridge.com/en/quote/02575.HK.md)

## Related News & Research

- [Xuanzhu Biopharmaceutical Wins CSRC Nod for H Share Full Circulation Plan](https://longbridge.com/en/news/282442087.md)
- [Xuanzhu Biopharmaceutical Sets March 30 Board Meeting for 2025 Results and Dividend Decision](https://longbridge.com/en/news/279271433.md)
- [Sihuan’s Xuanzhu Unit Posts Strong Phase III Lung Cancer Data for ALK Inhibitor Dirozalkib](https://longbridge.com/en/news/283291980.md)
- [Manulife Singapore to offer multi-cancer blood test starting May](https://longbridge.com/en/news/286710691.md)
- [Xuanzhu’s Breast Cancer Drug Bireociclib Delivers Strong Phase 3 Results Published in JAMA Oncology](https://longbridge.com/en/news/280309450.md)